Iron deficiency anaemia Haematological Disorders Anaemia
Conditions
Interventions
Subjects with iron deficiency anaemia will be recruited and will be randomly assigned to either a treatment (n = 15) or control group (n = 15). Subjects in the treatment group will receive 200 mg FeSO
Sponsors
Kings College London (UK)
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: 1. Females aged 18 to 50 years 2. Iron deficiency anaemia, defined as haemoglobin less than 12 g/dl, and mean corpuscular volume (MCV) less than 90 fl and serum ferritin less than 20 ug/l
Exclusion criteria
Exclusion criteria: 1. Suffer from serious chronic illness 2. Body mass index above 30 3. Smoker 4. Taking prescription drugs including contraceptive medicines 5. Regularly take medicines containing aspirin or ibuprofen 6. Pregnant or breastfeeding or are planning to become pregnant in the next two months 7. Moderately/severely elevated cholesterol (more than 6.0 mmol/l), as these factors affect either iron absorption or plasma isoprostane concentration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Plasma isoprostane concentration after daily iron treatment for 28 days. | — |
Secondary
| Measure | Time frame |
|---|---|
| The secondary outcome is serum NTBI. In addition to measuring the primary outcome (plasma isoprostanes) before and once after once daily ferrous sulphate treatment for 28 days, we will also measure serum NTBI before and once after daily ferrous sulphate treatment for 28 days in all subjects. | — |
Countries
United Kingdom
Outcome results
None listed